Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 6 X users

Readers on

mendeley: 10 Mendeley

Summary X

So far, Altmetric has seen 8 X posts from 6 X users, with an upper bound of 14,036 followers.

RT @jitcancer: #JITC Commentary: Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in precl…

27 Nov 2019

Reply Repost Favourite

#JITC Commentary: Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors https://t.co/6DLbYk54T7 https://t.co/Pt9tI1uhOS

26 Nov 2019

Reply Repost Favourite

RT @jitcancer: New #JITC Commentary: Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in p…

21 Nov 2019

Reply Repost Favourite

RT @jitcancer: New #JITC Commentary: Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in p…

20 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.